Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
NO is synthesized from l-arginine through the action of the nitric oxide synthase (NOS) family of enzymes, which includes three isoforms: endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS). iNOS-derived NO has been associated with the pathogenesis and progression of several diseases, including liver diseases, insulin resistance, obesity and diseases of the cardiovascular system.
|
31672462 |
2020 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The Glu298Asp is a single nucleotide polymorphism (SNP) in the eNOS gene related to the risk of cardiovascular disease.
|
31442681 |
2020 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Cytochrome P450 2D6 (CYP2D6) and endothelial nitric oxide synthase (eNOS) are important in the cardiovascular disease susceptibility and drug response.
|
31616043 |
2020 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Another molecule, Sirtuin 1 (SIRT1), a histone/protein deacetylase, regulates endothelial nitric oxide synthase and is involved in different aspects of cardiovascular disease, aging and stress resistance.
|
30030618 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This approach will allow for a better understanding of the role of eNOS genetic variants in cardiovascular disease progression and for cardiovascular drug therapy optimization.
|
31280192 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Asymmetric dimethylarginine (ADMA), an endothelial nitric oxide synthase inhibitor, plays a crucial role in the pathogenesis of various cardiovascular diseases associated with endothelial dysfunction.
|
30951718 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease.
|
30621010 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
With the development of molecular biological technology, the association between genes and diseases has drawn increasing attention of researchers; the endothelial nitric oxide synthase (eNOS) gene has been reported to be a candidate gene for cardiovascular disease (CHD).
|
29359785 |
2018 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Concomitant presence of CETP B1, NOS3 T and ANGPTL8 T alleles augments the risk of CVD and T2DM.
|
29973202 |
2018 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We discuss the role of rare NOS3 variants and further gene-gene interactions analysis for the development of novel therapies for cardiovascular diseases.
|
30398085 |
2018 |
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
These findings indicate that the phosphorylation of eEF1A1 by ROCK2 is physiologically important for eNOS expression and NO-mediated neuroprotection, and suggest that targeting endothelial ROCK2 and eEF1A may have therapeutic benefits in ischemic stroke and cardiovascular disease.
|
29353861 |
2018 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The risk also holds for the G894T and T-786C eNOS gene polymorphisms when excluding patients with dyslipidemia and cardiovascular diseases (p = 1.7·10<sup>-4</sup> and p = 3.2·10<sup>-5</sup> , respectively).
|
30101547 |
2018 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
In this review, we discuss the basic biochemical mechanisms of NOS3 regulation and the clinical and pharmacogenetic impact of NOS3 polymorphisms on cardiovascular diseases.
|
27569446 |
2017 |
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Impaired endothelial function, characterized by an imbalance in endothelial Nitric Oxide Synthase (eNOS) activity, precedes and accelerates the development of CVD.
|
28852041 |
2017 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Loss of endothelial BH<sub>4</sub> is observed in cardiovascular disease (CVD) states and results in decreased NO and increased superoxide (O<sub>2</sub><sup>-</sup>) generation via eNOS uncoupling.
|
28104455 |
2017 |
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The results of the present study provide evidence that GLP-1, but not GIP, has a protective effect on endothelial function associated with cardiovascular disease, as it is associated with increased eNOS expression and the levels of NO.
|
28565879 |
2017 |
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Increasing vascular NO levels following up-regulation of endothelial nitric oxide synthase (eNOS) is considered beneficial in cardiovascular disease.
|
27235748 |
2016 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Endothelial nitric oxide synthase (eNOS)-uncoupling links obesity-associated insulin resistance and type-II diabetes to the increased incidence of cardiovascular disease.
|
25034973 |
2014 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Endothelial nitric oxide synthase gene polymorphisms in cardiovascular disease.
|
25189395 |
2014 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We investigated effects of fish-oil supplementation on both classical and novel markers of endothelial function in subjects prospectively genotyped for the Asp298 endothelial nitric oxide synthase (eNOS) polymorphism and at moderate risk of cardiovascular disease (CVD).
|
25332321 |
2014 |
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In contrast, level of eNOS protein was considerably low in the CVD patients.
|
24587358 |
2014 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
It had been proved that the NOS3 polymorphism (rs1799983) was associated with the development of cardiovascular diseases.
|
23922896 |
2013 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Endothelial nitric oxide synthase (eNOS) gene polymorphisms have been associated with the pathogenesis of cardiovascular diseases, but few studies have evaluated the role of eNOS haplotypes on the risk and prognosis of heart failure (HF).
|
22290017 |
2012 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We therefore assessed the association of glaucoma with polymorphisms of NOS3 and CYBA previously associated with cardiovascular disease.
|
22919264 |
2012 |